

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (*EGFR*)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to *EGFR*-Tyrosine Kinase Inhibitors

Ji-Youn Han, MD, PhD¹, Ki Hyeong Lee, MD, PhD², Sang-We Kim, MD, PhD³, Young Joo Min, MD, PhD⁴, Eunkyung Cho, MD, PhD⁵, Youngjoo Lee, MD¹, Soo-Hyun Lee, MD¹, Hye Young Kim, MD, PhD¹, Geon Kook Lee, MD, PhD¹, Byung Ho Nam, PhD¹, Hyesun Han, MS⁶, Jina Jung, PhD⁶, Jin Soo Lee, MD, PhD¹

¹Center for Lung Cancer, National Cancer Center, Goyang, ²Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, ³Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ⁴Department of Internal Medicine, Ulsan University Hospital, Ulsan, ⁵Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, ⁶Clinical Research Team, Hanmi Pharmaceutical Co., Ltd., Seoul, Korea

Supplementary Data


Table of Contents

Supplementary Table 1	2
Supplementary Fig. S1	3

Supplementary Table 1. Comparison of *EGFR* T79M mutation detected in tumor tissue and plasma samples

	Tumor T79M			Total
	Positive	Negative	Unknown	
Plasma T79M				
Positive	11	6	1	18
Negative	8	12	1	21
Total	19	18	2	39
Concordance (%)				63
Sensitivity (%)				58
Specificity (%)				68
Positive predictive value (%)				65
Negative predictive value (%)				62

EGFR, epidermal growth factor receptor.



Supplementary Fig. S1. Kaplan-Meier curves for progression-free survival for patients with epidermal growth factor receptor (*EGFR*) T790M mutation in tumor tissue (A), *EGFR* T790M or *PIK3CA* mutation in tumor tissue (B), *EGFR* T790M mutation in plasma (C), and *EGFR* T790M or *PIK3CA* mutations in tumor tissue and/or plasma. mt, mutation.